JAK2 and myeloproliferative neoplasm: Previously published data have demonstrated that JAK2‐V617F‐positive MPN cells display PD‐L1, a major immune checkpoint antigen mediating immunological resistance in neoplastic cells in diverse hematologic malignancies.14